Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne’s syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues-Reference-Cited by-同舟云学术

Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne’s syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues

Published:2000-12 Issue:11 Volume:60 Page:1611-1619
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Dabholkar Meenakshi,Thornton Keith,Vionnet Justine,Bostick-Bruton Frieda,Yu Jing Jie,Reed Eddie

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference45 articles.

1. Reed E, Platinum analogs. In: Cancer—Principles and Practice of Oncology (Eds. DeVita VT, Hellman S and Rosenberg SA), 4th Edn, pp. 390–399. J.B. Lippincott, Philadelphia, 1993.

2. Reed E and Kohn KW, Cisplatin and platinum analogs. In: Cancer Chemotherapy—Principles and Practice (Eds. Chabner BA and Collins J), pp. 465–490. J.B. Lippincott, Philadelphia, 1990.

3. DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II);Sheibani;Biochemistry,1989

4. Resistance to alkylating agents and cisplatin;Perez;Pharmacol Ther,1990

5. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines;Masuda;Cancer Res,1988

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer;Journal of Ovarian Research;2024-02-12

2. Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets;Cancers;2022-12-18

3. Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance;Drug Resistance Updates;2021-09

4. MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells;Journal of Cancer;2019

5. Origins based clinical and molecular complexities of epithelial ovarian cancer;International Journal of Biological Macromolecules;2018-10